| scholarly article | Q13442814 |
| P50 | author | Ines Barone | Q59688868 |
| P2093 | author name string | Amanda Beyer | |
| Jennifer Selever | |||
| Matthew H Herynk | |||
| Suzanne A W Fuqua | |||
| Sebastiano Andò | |||
| Cinzia Giordano | |||
| Yukun Cui | |||
| Arnoldo Corona-Rodriguez | |||
| P2860 | cites work | pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167 | Q24533505 |
| Hypersensitive K303R oestrogen receptor-alpha variant not found in invasive carcinomas | Q24796885 | ||
| The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study | Q25257794 | ||
| The consensus coding sequences of human breast and colorectal cancers | Q27861035 | ||
| Patterns of somatic mutation in human cancer genomes | Q29547841 | ||
| Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo | Q30304578 | ||
| Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase | Q30439814 | ||
| The activation of Akt/PKB signaling pathway and cell survival. | Q34405519 | ||
| Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. | Q34578381 | ||
| Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer | Q35049854 | ||
| What do we know about the mechanisms of aromatase inhibitor resistance? | Q35691554 | ||
| Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. | Q35786706 | ||
| Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer | Q35794355 | ||
| AKT/PKB signaling mechanisms in cancer and chemoresistance | Q35966433 | ||
| Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy | Q35991001 | ||
| Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy | Q36559283 | ||
| Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor | Q39971693 | ||
| Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells | Q40195766 | ||
| Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. | Q40383001 | ||
| Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole | Q40408917 | ||
| The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation | Q40427640 | ||
| Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. | Q40479849 | ||
| Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance | Q40536641 | ||
| Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast | Q40575607 | ||
| Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens | Q40614262 | ||
| Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines | Q41198739 | ||
| Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells | Q41291278 | ||
| Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation | Q41859532 | ||
| Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation | Q42442143 | ||
| Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture | Q42815851 | ||
| Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. | Q43708526 | ||
| No hypersensitive estrogen receptor-alpha mutation (K303R) in Japanese breast carcinomas | Q44803003 | ||
| Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members | Q45267497 | ||
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer | Q46586619 | ||
| Adjuvant aromatase inhibitors for breast cancer | Q46638001 | ||
| Aromatase inhibitors--a triumph of translational oncology | Q46871157 | ||
| Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. | Q52276783 | ||
| The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. | Q52514375 | ||
| Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. | Q54172521 | ||
| Estrogen receptor alpha mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women. | Q54795647 | ||
| 45 Assay of aromatase activity | Q67842856 | ||
| Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation | Q67982627 | ||
| A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions | Q74181062 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 4724-4732 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway | |
| P478 | volume | 69 |
| Q34119065 | A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions |
| Q35112392 | AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. |
| Q36246651 | Absence of the K303R estrogen receptor α mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment |
| Q34666075 | Acetylation and nuclear receptor action |
| Q36449789 | Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk |
| Q37851027 | Bioengineering approaches to study multidrug resistance in tumor cells |
| Q92648911 | Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression |
| Q88792280 | Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers |
| Q48026385 | Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma |
| Q36030787 | Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer. |
| Q36589361 | Derailed estrogen signaling and breast cancer: an authentic couple. |
| Q38913843 | Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. |
| Q37013898 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer |
| Q34010413 | Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight |
| Q35794268 | Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. |
| Q34112728 | Estrogen receptor mutations and changes in downstream gene expression and signaling |
| Q90399244 | Ethanol extract of Ligustrum lucidum Ait. leaves suppressed hepatocellular carcinoma in vitro and in vivo |
| Q36078905 | Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells |
| Q45836821 | Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study |
| Q39208543 | Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma |
| Q35786712 | Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression |
| Q54399355 | Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. |
| Q38372445 | Future perspectives for mTOR inhibitors in renal cell cancer treatment |
| Q36690093 | G9a-mediated methylation of ERα links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression. |
| Q33656801 | Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. |
| Q38707618 | IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. |
| Q34010406 | Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells |
| Q28308069 | Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α |
| Q27011221 | Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA |
| Q64981395 | PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT. |
| Q41189355 | Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor |
| Q34070890 | Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity |
| Q38984903 | Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth |
| Q57112955 | The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer |
Search more.